Abstract
Eleven novel chalcone analogs having a 2-phenylimino-3-phenylthiazolidin-4-one core structure were designed, synthesized and investigated for cytotoxicity against murine B16 and L1210 cancer cells. Single crystal X-ray structure analyses confirmed that these chalcone analogs adopt a Z-geometry about the alkene bond. One of the compounds, 3j, which possesses a 2-chloro-5-bromo substitution in the phenyl moiety, showed moderate cytotoxicity against murine (B16) and human melanoma (MDA-MB-435) cell lines with an IC50 value of 57 and 12 µ M, respectively. At 30 µ M, compound 3j had virtually no effects on the microtubules in A10 cells.
Keywords: Chalcones, 2-Phenylimino-3-phenylthiazolidin-4-one, Cytotoxicity, Tubulin, murine (B16), melanoma, Single crystal X-ray structure analyses, antimalarial, Thiazolidinone, antischistosomal agents, phenylimine substituents, S. epidermidis, MTT assay, antimitotic agents
Letters in Drug Design & Discovery
Title: Design, Synthesis and Cytotoxicity of Chalcone Analogs Derived from 2-Phenylimino-3-phenylthiazolidin-4-one
Volume: 8 Issue: 8
Author(s): Vijay Satam, Ravi Kumar Bandi, Ajaya Kumar Behera, Bijay Kumar Mishra, Olivia Brockway, Samuel Tzou, Matthias Zeller, Moses Lee and Hari Pati
Affiliation:
Keywords: Chalcones, 2-Phenylimino-3-phenylthiazolidin-4-one, Cytotoxicity, Tubulin, murine (B16), melanoma, Single crystal X-ray structure analyses, antimalarial, Thiazolidinone, antischistosomal agents, phenylimine substituents, S. epidermidis, MTT assay, antimitotic agents
Abstract: Eleven novel chalcone analogs having a 2-phenylimino-3-phenylthiazolidin-4-one core structure were designed, synthesized and investigated for cytotoxicity against murine B16 and L1210 cancer cells. Single crystal X-ray structure analyses confirmed that these chalcone analogs adopt a Z-geometry about the alkene bond. One of the compounds, 3j, which possesses a 2-chloro-5-bromo substitution in the phenyl moiety, showed moderate cytotoxicity against murine (B16) and human melanoma (MDA-MB-435) cell lines with an IC50 value of 57 and 12 µ M, respectively. At 30 µ M, compound 3j had virtually no effects on the microtubules in A10 cells.
Export Options
About this article
Cite this article as:
Satam Vijay, Bandi Ravi Kumar, Behera Ajaya Kumar, Mishra Bijay Kumar, Brockway Olivia, Tzou Samuel, Zeller Matthias, Lee Moses and Pati Hari, Design, Synthesis and Cytotoxicity of Chalcone Analogs Derived from 2-Phenylimino-3-phenylthiazolidin-4-one, Letters in Drug Design & Discovery 2011; 8 (8) . https://dx.doi.org/10.2174/157018011796576033
DOI https://dx.doi.org/10.2174/157018011796576033 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Nanocarriers Based Anticancer Drugs: Current Scenario and Future Perceptions
Current Drug Targets Nanomedicines as Cancer Therapeutics: Current Status
Current Cancer Drug Targets Micro/Nanoparticle Design and Fabrication for Pharmaceutical Drug Preparation and Delivery Applications
Current Drug Therapy Blood-Brain-Barrier Models for the Investigation of Transporter- and Receptor-Mediated Amyloid-β Clearance in Alzheimers Disease
Current Alzheimer Research Improvement of Nonviral Gene Therapy by Epstein-Barr Virus (EBV)-based Plasmid Vectors
Current Gene Therapy Application of Recombinant and Non-Recombinant Peptides in the Determination of Tumor Response to Cancer Therapy
Current Pharmaceutical Biotechnology Recent Advances in Small Molecule Inhibitors of VEGFR and EGFR Signaling Pathways
Current Topics in Medicinal Chemistry Mango Polyphenols and Its Protective Effects on Diseases Associated to Oxidative Stress
Current Pharmaceutical Biotechnology Overcoming the Hurdles of Tumor Immunity by Targeting Regulatory Pathways in Innate and Adaptive Immune Cells
Current Pharmaceutical Design Etiopathogenesis, Classical Immunotherapy and Innovative Nanotherapeutics for Inflammatory Neurological Disorders
Current Nanoscience Approaches for Developing Novel Microtubule Targeting Agents (MTAs) for Therapeutic Exploitation
Current Pharmaceutical Design The Complexes of Drugs with Carbohydrate-Containing Plant Metabolites as Pharmacologically Promising Agents
Mini-Reviews in Medicinal Chemistry Study of Serum Soluble Programmed Death Ligand 1 as a Prognostic Factor in Hepatocellular Carcinoma in Egyptian Patients
Current Cancer Drug Targets Safety of Systemic Biologic Agents in the Treatment of Non-malignant Skin Disorders
Current Drug Safety The Impact of Combination Therapy with a-Blockers and 5ARIs on the Progression of BPH
Current Drug Targets A Comprehensive Review on Chrysin: Emphasis on Molecular Targets, Pharmacological Actions and Bio-pharmaceutical Aspects
Current Drug Targets Epigenetic Lesions in Malignant Melanoma
Current Pharmaceutical Biotechnology The physics for the formation of cell-in-cell structures.
Current Molecular Medicine The Endocrine System and Sarcopenia: Potential Therapeutic Benefits
Current Aging Science New Directions for Clinical Trials of Targeted Alpha Therapy for Metastatic Melanoma
Current Radiopharmaceuticals